Published Online:14 Oct 2011https://doi.org/10.2217/rme.11.67
Abstract
Developing countries such as China, India and Brazil are making large investments in the stem cell field. Here we argue that hands-on involvement in the field by these countries is essential if the products developed are going to be locally relevant, affordable and appropriate. However, stem cells are a high-risk investment and any global health impacts are still likely to be far off. Even if they are eventually successful, better clinical oversight and measures to ensure access are required for stem cells to have a substantial and equitable impact.
Papers of special note have been highlighted as: ▪▪ of considerable interest
Bibliography
- 1 McMahon DS, Thorsteinsdóttir H, Singer PA, Daar AS. Cultivating regenerative medicine innovation in China. Regen. Med.5(1),35–44 (2010).▪▪ Presents an analysis of regenerative medicine innovation in China, including its sucesses and challenges.
- 2 Sogayar MC, Campos de Carvalho AC. Stem cell research in Brazil: incentives, barriers and perspectives. In: World Stem Cell Report. Genetics Policy Institute, FL, USA, 179–184 (2010).
- 3 Leite M. Overcoming opposition: Brazil banks on stem cells. Science324(5923),26–26 (2009).
- 4 Greenwood H, Singer P, Downey G, Martin D, Thorsteinsdóttir H, Daar A. Regenerative medicine and the developing world. PLoS Med.3(9),e381 (2006).▪▪ Identifies the most relevant applications for regenerative medicine in the developing world, demonstrating the relevance of stem cells to local health needs.
- 5 Greenwood HL, Thorsteinsdóttir H, Perry G, Renihan J, Singer PA, Daar AS. Regenerative medicine: new opportunities for developing countries. Int. J. Biotechnol.8(1),60–77 (2006).
- 6 McMahon DS, Singer PA, Daar AS, Thorsteinsdóttir H. Regenerative medicine in Brazil: small but innovative. Regen. Med.5(6),863–876 (2010).▪▪ Presents an analysis of regenerative medicine innovation in Brazil, including its sucesses and challenges.
- 7 Lander B, Thorsteinsdóttir H, Singer PA, Daar AS. Harnessing stem cells for health needs in India. Cell Stem Cell3(1),11–15 (2008).▪▪ Presents an analysis of regenerative medicine innovation in India, including its sucesses and challenges.
- 8 Jamison DT. Investing in Health. In: Disease Control Priorities in Developing Countries. Jamison DT, Breman JG, Measham AR et al. (Eds). World Bank, DC, USA, 1–42 (2006).
- 9 Polanczyk C, Ribeiro J. Coronary artery disease in Brazil: contemporary management and future perspectives. Heart95(11),870–876 (2009).
- 10 Tura B, Martino H, Gowdak L et al. Multicenter randomized trial of cell therapy in cardiopathies – MiHeart Study. Trials8,2 (2007).
- 11 Gajewski J, Robinson P. Do affluent societies have the only options for the best therapy? Leukemia21(3),387–388 (2007).▪▪ Presents key differences in bone marrow transplant protocols between developed countries with China and India. These differences make locally developed protocols more culturally relevant and affordable.
- 101 WHO. Preventing chronic diseases: a vital investment (2005) www.who.int/chp/chronic_disease_report/contents/en/index.html▪▪ Shows the burden and impact of chronic diseases in the developing world.
- 102 C-TRACER. A comprehensive report on the reserach activities of C-TRACER at the LV Prasad Eye Institue, Hyderabad, India (2010) www.fchampalimaud.org/images/uploads/C-TRACER_June_2010.pdf
- 103 IBOPE Inteligência. População brasileira declara apoiar o uso de células-tronco para recuperação e tratamento de pessoas com doenças graves [Portuguese only]. Opinião Pública, Notícias (2008) www.ibope.com.br/calandraWeb/servlet/CalandraRedirect?temp=5&proj=PortalIBOPE&pub=T&db=caldb&comp=Not%EDcias&docid=0D5622636BD74F018325740200621078
